FFPRHC Guidance (October 2004) Contraceptive choices for young people

Journal of Family Planning and Reproductive Health Care

Volumn 30, Issue 4, 2004, Pages 237-251

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DIANE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL;

CONDOM; CONFIDENTIALITY; CONTRACEPTION; DEPRESSION; HUMAN; INTERPERSONAL COMMUNICATION; INTRAUTERINE CONTRACEPTIVE DEVICE; MOOD DISORDER; PRACTICE GUIDELINE; REVIEW; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; CONTRACEPTION; FEMALE; GREAT BRITAIN; HUMANS; PREGNANCY; PREGNANCY IN ADOLESCENCE; REPRODUCTIVE HEALTH SERVICES;

EID: 7044251800     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/0000000042177018     Document Type: Review

References (189)

1. Department of Health. The Children's Act 1989 - Guidance and Regulations. London, UK: Department of Health, 1997. http://www.lbcma.org.uk/guidelines2. pdf.
2. Children (Scotland) Act. London, UK: The Stationary Office, 1995.
3. Teenage Pregnancy Unit. Statistics - Conception Statistics for England, 1998-2001. London, UK; Teenage Pregnancy Unit, Department of Health, 2001. http://www.info.doh.gov.uk/tpu/tpu.nsf.
4. Wellings K, Nanchahal K, Macdowall W, et al. Sexual behaviour in Britain: early heterosexual experience. Lancet 2001; 358: 1843-1850.
5. Department of Health. The National Sexual Health Strategy for Health and HIV. Implementation Action Plan. London, UK: Department of Health, 2002: 1-17.
6. Scottish Executive Proposal to the Scottish Executive. Enhancing Sexual Wellbeing in Scotland. A Sexual Health and Relationships Strategy. Edinburgh, UK: Scottish Executive, 2003. http://www.scotland.gov.uk/sexualhealthstrategy/.
7. General Medical Council (GMC). Maintaining Good Medical Practice. London, UK: GMC, 1998.
8. Medical Defence Unit (MDU). Consent to Treatment. London, UK: MDU Ltd, 1996.
9. Department of Health. Reference Guide to Consent for Examination or Treatment. London, UK: Department of Health, 2001. http://www.doh.gov.uk.
10. British Medical Association (BMA). The Impact of the Human Rights Act 1998 on Medical Decision Making. London, UK; BMA, 2000, 1. http://www.bma.org. uk.
11. General Medical Council (GMC). Seeking Patient's Consent: The Ethical Considerations. London, UK: GMC, 1998.
12. British Medical Association (BMA). Consent Toolkit (2nd edn). London, UK: BMA, 2003, 1-17. http://www.bma.org.uk.
13. Re C. Refusal of Treatment. 1WLR 290. 1994.
14. Her Majesty's Stationery Office (HMSO). Age of Legal Capacity (Scotland) Act 1991. London, UK: HMSO, 1991. http://www. legislation.hmso.gov.uk/acts/ acts1991/ukpga_19910050_e2_1.htm.
15. Human and Constitutional Rights. Gillick v West Norfolk and Wisbech AHA (1986) AC 112, (1985) 3 WLR 830, (1985) 3 A11 ER 402, HL. http://www.hrcr.org/ safrice/childrens_rights/Gillick_West Norfolk.htm.
16. Age of Majority Act, 1985 No. 2/1985. http://www.acts.ie.
17. British Medical Association. Adults with Incapacity (Scotland) Act 2000. http://www.scotland-legislation.hmso.gov.uk/legislation/ scotland/acts2000/ 20000004.htm. 2000.
18. British Medical Association. Medical Treatment for Adults with Incapacity: Guidance on Ethical and Medico-legal Issues in Scotland. http://www.bma.org.uk/ap.nsf/Content/adults+with+incapacity+-+scotland. 2002.
19. British Medical Association Board of Science and Education. Adolescent Health. London, UK: BMA Publications, 2003. http://www.bma.org.uk.
20. Sexual Offences Act 2003. Chapter 42. http://www.legislation.hmso. gov.uk/acts/acts 2003/20030042.htm.2004.
21. Criminal Law (Consolidation) (Scotland) Act 1995 (c.39) Part 1 Sexual Offences. ISBN 0105439959. London, UK: The Stationery Office, 2004.
22. Gordon GH. Chapters 33-36. In: Christie MGA (ed.), The Criminal Law of Scotland. Edinburgh, UK, W. Green, 2001; 507-555.
23. Sexual Offences (Amendment) Act 2000. London, UK: Queen's Printers of Acts of Parliament, Her Majesty's Stationery Office, 2000. http://www.hmso.gov. uk/acts/acts2000/20000044.htm.
24. Suffolk Area Child Protection Committee. Guidance on Consent and Child Protection Issues for Those Involved in Promoting Young People's Sexual Health in Suffolk. July 2002. http://www.suffolkcc. gov.uk/sacpc/childProt.html.
25. Wight D, Henderson M, Raab G, et al. Extent of regretted sexual intercourse among young teenagers in Scotland: a cross sectional survey. BMJ 2000; 320: 1243-1244.
26. Dickson N, Paul C, Herbison S, et al. First sexual intercourse: age, coercion, and later regrets reported by a birth control cohort. BMJ 1998; 316: 29-33.
27. Department of Health, Home Office, and Department of Education and Employment. Working Together to Safeguard Children. London, UK: The Stationery Office, 1999; 1: 1-119. http://www.doh.gov.uk.
28. Scottish Executive. Protecting Children and Young People: Framework for Standards. ISBN 0-7559-4087-3. Edinburgh, UK: Scottish Executive, 2004; 1-33.
29. Department of Health. What To Do If You Are Worried a Child is Being Abused (Summary). Children's Services Guidance: Best Practice Guidance. London, UK: Department of Health, 2003; 1-32. http://www.dh.gov.uk/assetRoot/04/06/13/ 04/04061304.pdf.
30. Thomas A, Forster G, Robinson A, et al. National Guideline on the Management of Suspected Sexually Transmitted Infections in Children and Young People. http://www.bashh.org/ceguidelines.html. 2002.
31. British Medical Association (BMA). Confidentiality and People Under 16. Guidance issued jointly by the BMA, GMSC, HEA, Brook Advisory Centres, FPA and RCGP. London, UK: BMA Publications Online, 1994. http://www.bma.org.uk.
32. NHS Scotland. NHS Code of Practice on Protecting Patient Confidentiality. Edinburgh, UK: Scottish Executive, 2003. http://www.scotland.gov.uk.
33. Royal College of General Practitioners (RCGN) and Royal College of Nursing (RCN). Getting it Right for Teenagers in Your Practice. London, UK: RCGN with the RCN, 2002; 1-6. http://www.info.doh.gov.uk/tpu/tpu.nsf.
34. Royal College of General Practitioners, General Practitioners Committee, British Medical Association, Royal College of Nursing, and Medical Defence Union. Confidentiality and Young People. Improving Teenagers' Uptake of Sexual and Other Health Advice. Publisher, Location, 2000; 1-61. http://www.info.doh. gov.uk/ tpu/tpu.nsf.
35. Teenage Pregnancy Unit. Guidance for Youth Workers on Providing Information and Referring Young People to Contraceptive and Sexual Health Services. London, UK: Teenage Pregnancy Unit, Department of Health, 2001; 1-15. http://www.info.doh.gov.uk/tpu/tpu.nsf.
36. Department of Health. BMA Conference of Medical Royal Colleges. Child Protection: Medical Responsibilities. Guidance for Doctors Working with Child Protection Agencies. London, UK: Department of Health, 2000, 1994.
37. British Medical Association (BMA). Confidentiality and Disclosure of Health Information. London, UK: BMA Publications Online, 14 October 1999. http://www.bma.org.uk.
38. Department of Health. Confidentiality. NHS Code of Practice. London, UK: Department of Health, 2003.
39. Department for Education and Skills. Every Child Matters. 2004. London, UK: Department of Education and Skills. http://www.dfes.gov.uk/ everychildmatters/pdfs.
40. World Health Organization (WHO). Medical Eligibility Criteria for Contraceptive Use: Improving Access to Quality Care in Family Planning (3rd edn). Geneva, Switzerland: WHO, 2004.
41. World Health Organization Task Force on Adolescent Reproductive Health. World Health Organization multicentre study on menstrual and ovulatory patterns in adolescent girls. II. Longitudinal study of menstrual patterns in the early postmenarcheal period, duration of bleeding episodes and menstrual cycles. J Adolesc Health Care 1986; 7: 236-244.
42. Borsos A, Lampe L, Balogh A, et al. Ovarian function after the menarche and hormonal contraception. Int J Gynaecol Obstet 1988; 27: 249-253.
43. Cromer B, Harel Z. Adolescents: at increased risk for osteoporosis? Clin Pediatr 2000; 39: 565-574.
44. Theinz G, Buchs B, Nizzolo R, et al. Longitudinal monitoring of bone mass accumulation in health adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060-1065.
45. Matkovic V, Jelic T, Wardlaw GM. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: inference from a cross-sectional model. J Clin Invest 1994; 93: 799-808.
46. Hergenroeder AC. Bone mineralization, hypothalamic amenorrhoea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995; 126: 683-689.
47. Teegarden D, Proulx WR, Martin BR. Peak bone mass in young women. J Bone Miner Res 1995; 10: 711-715.
48. O'Brien KO, Nathanson MS, Mancini J, et al. Calcium absorption is significantly higher in adolescents during pregnancy than in the early postpartum period. Am J Clin Nutr 2003; 78: 1188-1193.
49. Bezerra FF, Laboissiere FP, King JC, et al. Pregnancy and lactation affect markers of calcium and bone metabolism differently in adolescent and adult women with low calcium intakes. J Nutr 2002; 132: 2183-2187.
50. Chan GM, Ronald N, Slater P, et al. Decreased bone mineral status in lactating adolescent mothers. Pediatrics 1982; 101: 767-770.
51. Lim SW, Rieder J, Coupey SM, et al. Depot medroxyprogesterone acetate use in inner-city, minority adolescents: continuation rates and characteristics of long-term users. Arch Pediatr Adolesc Med 1999; 153: 1068-1072.
52. Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol 1999; 12: 90-94.
53. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health 2003; 32: 257-259.
54. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br J Obstet Gynaecol 2001; 108: 1214-1221.
55. Gbolade BA. Depo-Provera and bone density. Faculty Aid to CPD Topics (FACT). J Fam Plann Reprod Health Care 2002; 28: 7-11.
56. Scholes D, LaCroix AZ, Ott SM, et al. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 1999; 93: 233-238.
57. Cundy T, Cornish J, Evans MC, et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 1994; 308: 247-248.
58. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303: 13-16.
59. Tharnprisarn W, Taneepanichskul S. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: a cross-sectional study in young Thai women. Contraception 2002; 66: 101-103.
60. Cromer BA, McArdle Blair J, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996; 129: 671-676.
61. Edwards CP, Hertweck SP, Perlman SE, et al. A prospective study evaluating the effects of Depo Provera on bone mineral density in adolescent females: a preliminary report. J Pediatr Adolesc Gynecol 1998; 11: 201-210.
62. Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13: 581-587.
63. Cromer B. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol 2003; 15: 353-357.
64. Lloyd T, Taylor DS, Lin HM. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril 2000; 74: 734-738.
65. MacDougall J, Davies MC, Overton CE, et al. Bone density in a population of long-term oral contraceptive pill users does not differ from that in menstruating women. Br J Fam Plann 1999; 25: 96-100.
66. Casterlo-Branco C, Vicente JJ, Pons F. Bone mineral density in young, hypothalamic oligomenorrhoeic women treated with oral contraceptives. J Reprod Med 2001; 46: 875-879.
67. Polatti F, Perotti F, Filippa N. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995; 51: 221-224.
68. Beerthuizen R, van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestogen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000; 15: 118-122.
69. The British Co-operative Clinical Group. Provision of sexual health care for adolescents in genitourinary medicine clinics in the United Kingdom. Genitourin Med 1997; 73: 453-456.
70. Underhill G, Hewitt G, McLean L, et al. Who has chlamydia? The prevalence of genital tract Chlamydia trachomatis within Portsmouth and South East Hampshire, UK. J Fam Plann Reprod Health Care 2003; 29(1): 17-20.
71. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2003). Emergency contraception. J Fam Plann Reprod Health Care 2003; 29(2): 9-16.
72. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (October 2003). First prescription of combined oral contraception. J Fam Plann Reprod Health Care 2003; 29(4): 209-223.
73. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (January 2004). The copper intrauterine device as long-term contraception. J Fam Plann Reprod Health Care 2004; 30: 29-42.
74. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004; 30: 99-108.
75. Weller S, Davis AR. Condom effectiveness in reducing heterosexual HIV transmission. The Cochrane Library, Issue 1, 2003 1, CD003255, 2002. http://update-software.com [Accessed 8 June 2004].
76. National Institute of Allergy and Infectious Diseases, National Institutes of Health Department of Health and Human Services. Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention. Bethesda, MD: Department of Health and Human Services, National Institutes of Health, 2000; 1-27. http://www.niad.nhi.gov/dmid/stds/ condomreport/pdf.
77. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Clinical Effectiveness Guideline for the Management of Chlamydia trachomatis Genital Tract Infection. London, UK: BASHH, 2001. http://www.bashh.org/guidelines/2002C4A%2009% 2001c.pdf.
78. Warner L, Newman DR, Austin HD, et al. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol 2004; 159: 242-251.
79. Clinical Effectiveness Group (BASHH). 2001 National Guidelines for the Management of Genital Herpes. http://www.bashh.org/ guidelines [Accessed June 2004].
80. Casper C, Wald A. Condom use and the prevention of genital herpes acquisition. Herpes 2002; 9: 10-14.
81. Clinical Effectiveness Group (BASHH). National Guideline for the Management of Anogenital Warts, http://www.bashh.org/guidelines/ hpv/%2003%2002b.pdf. 2002.
82. World Health Organization (WHO). WHO/CONRAD Technical Consultation on Nonoxynol-9. Geneva, Switzerland: WHO, 2001.
83. Dawe F, Meltzer H. Contraception and Sexual Health 2002. London, UK: HMSO, 2003; 1-49. http://www.statistics.gov.uk.
84. DiClemente RJ, Wingwood GM, Crosby R, et al. Condom carrying is not associated with condom use and lower prevalence of sexually transmitted diseases among minority adolescent females. Sex Transm Dis 2001; 28: 444-447.
85. Tulloch HE, McCaul KD, Miltenberger RG, et al. Partner communication skills and condom use among college couples. J Am Coll Health 2004; 52: 263-267.
86. Ineichen B, Logie J, Rowlands S, et al. Patterns of prescription of PC4 by general practitioners in England and Wales. Eur J Contracept Reprod Health Care 2000; 5: 241-247.
87. Clark LR. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J Pediatr Adolesc Gynecol 2001; 14: 153-162.
88. Davidson AR, Kalmuss D. Topics for our times: Norplant coercion - an overstated threat. Am J Public Health 1997; 87: 550.
89. Peipert JF, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol 1993; 82: 112.
90. Silverman J, Torres A, Forrest JD. Barriers to contraceptive services. Fam Plann Perspect 1987; 19: 94.
91. Davis AR, Teal SB. Controversies in adolescent hormonal contraception. Obstet Gynecol Clin North Am 2003; 30: 391-406.
92. Scott CS, Shifman L, Orr L, et al. Hispanic and black American adolescents' beliefs relating to sexuality and contraception. Adolescence 1988; XXIII: 667-688.
93. Tanfer K, Wierzbicki S, Payn B. Why are U.S. women not using long-acting contraceptives? Fam Plann Perspect 2000; 32: 176-183.
94. Cushman LF, Davidson AR, Kalmuss D, et al. Beliefs about Norplant® implants among low income urban women. Contraception 1996;53:285-291.
95. Gold MA, Coupey SM. Young women's attitudes toward injectable and implantable contraceptives. J Pediatr Adolesc Gynecol 1998; 11: 17.
96. Wiemann CM, Berenson AB. An investigation into why adolescents may reject Norplant. Pediatrics 1996; 97: 185-191.
97. Moore PJ, Adler NE, Kegeles SM. Adolescents and the contraceptive pill: the impact of beliefs on intentions and use. Obstet Gynecol 1996; 88: 48S-56S.
98. Kuiper H, Miller S, Martinez E, et al. Urban adolescent females' views on the implant and contraceptive decision-making: a double paradox. Fam Plann Perspect 1997; 29: 167-172.
99. Herold E, Goodwin M. Perceived side effects of oral contraceptives among adolescent girls. Can Med Assoc J 1980; 123: 1022-1023.
100. Balassone ML. Risk of contraceptive discontinuation among adolescents. J Adolesc Health 1989; 10: 527.
101. Zabin LS, Stark HA, Emerson MR. Reasons for delay in contraceptive clinic utilization. Adolescent clinic and non-clinic populations compared. J Adolesc Health 1991; 12: 225.
102. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans. Hormonal Contraception and Postmenopausal Hormonal Therapy. Lyon, France: WHO IARC, 1999.
103. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestogen dose and use characteristics of oral contraceptives. Am J Epidemiol 2000; 152: 233-241.
104. The World Health Organization (WHO) Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer 1991; 49: 191-195.
105. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993; 82: 931-935.
106. Cancer and Steroid Hormones (CASH). Combined oral contraceptive use and risk of endometrial cancer. JAMA 1987; 257: 796-800.
107. Liang AP, Levenson AG, Layde PM, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 1983; 249: 2909-2912.
108. Smith JS, Green J. Cervical cancer and use of hormonal contraception: a systematic review. Lancet 2003; 361: 1159-1167.
109. Moreno V, Bosch FX, Munoz N. Effects of oral contraceptives on risk of cervical cancer in women with human papilloma virus infection: the IARC multicentric case-control study. Lancet 2002; 399: 1085-1092.
110. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control 2003; 14: 485-495.
111. Thomas DB, Ye Z, Ray RM. Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1995; 51: 25-31.
112. Thomas DB, Ray RM. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1995; 52: 307-312.
113. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
114. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
115. Wingo PA, Lee NC, Ory HW, et al. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Cancer 1993; 71: 1506-1517.
116. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995; 273: 799-804.
117. Chilvers CE. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge. Drug Saf 1996; 15: 212-218.
118. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000; 151: 396-403.
119. Committee on Safety of Medicines (CSM). Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Current Problems in Pharmacovigilance 1999; 25: 1-2.
120. World Health Organization (WHO). Effect of different progestogens in low oestrogen containing oral contraceptives on venous thromboembolism. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-1582.
121. Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190-1195.
122. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187-196.
123. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146.
124. Lewis MA, Heinemann L, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens; role of bias in observational research. Contraception 1996; 54: 5-13.
125. World Health Organization (WHO). Cardiovascular disease and use of oral and injectable progestogen only contraceptives and combined injectable contraceptives. Results of an international, multicentre, case control study. Contraception 1998; 57: 315-324.
126. World Health Organization (WHO). Venous thromboembolic disease and combined oral contraceptives: results of a multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 345: 1575-1582.
127. Emans SJ, Grace E, Woods ER, et al. Adolescents' compliance with the use of oral contraceptives. JAMA 1987; 257: 3377-3381.
128. Malina R. Normal weight gain in growing children. Healthy Weight Journal 1999; 13: 1-4.
129. Gallo MF, Grimes DA, Schulz KF, et al. Combination contraceptives: effects on weight. The Cochrane Library, Issue 4, 2003. http://update-software. com [Accessed May 2004].
130. Rosenthal SL, Cotton S, Ready JN, et al. Adolescents' attitudes and experiences regarding levonorgestrel 100 mcg/ethinyl estradiol 20 meg. J Pediatr Adolesc Gynecol 2002; 15: 301-305.
131. Lloyd T, Lin HM, Matthews AE, et al. Oral contraceptive use by teenage women does not affect body composition. Obstet Gynecol 2002; 100: 235-239.
132. Cromer BA, Smith RD, McArdle Blair J, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94: 687-694.
133. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health 1998; 23: 81-88.
134. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002; 15: 79-82.
135. Maison SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol 1997; 10: 18-23.
136. Risser WL, Gefter LR, Barratt MS, et al. Weight changes in adolescenls who use hormonal contraception. J Adolesc Health 1999; 24: 433-436.
137. Templeman C, Boyd H, Hertweck SP. Depomedroxyprogesterone acetate use and weight gain among adolescents. J Pediatr Adolesc Gynecol 2000; 13: 45-46.
138. Harel Z, Biro FM, Kollar LM, et al. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptive Depo-Provera and Norplant. J Adolesc Health 1996; 19: 118-123.
139. Cardamakis E, Georgopoulos A, Folopoulos A, et al. Clinical experience with Norplant subdermal implant system as long-term contraception during adolescence. Eur J Contracept Reprod Health Care 2002; 7: 36-40.
140. Berenson AB, Wiemann CM, Rickerr VI, et al. Contraceptive outcomes among adolescents prescribed Norplant implants versus oral contraceptives after one year of use. Am J Obstet Gynecol 1997; 176: 586-592.
141. Suman VJ, Van Winter JT, Evans MP, et al. Levonorgestrel contraceplive implants in female patients 14 to 21 years old. Mayo Clin Proc 1998; 73: 10-16.
142. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003; 188: 1158-1160.
143. Leyden J, Shalita A, Hordinskly M, et al. Efficacy of a low dose oral contraceptive containing 20 microg of ethinyl oestradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol 2002; 47: 399-409.
144. Rowlands S, Devalia H, Lawrenson R. Preferential prescribing of type of combined oral contraceptive pill by general practitioners to teenagers with acne. Eur J Contracept Reprod Health Care 2001; 6: 9-13.
145. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
146. Committee on Safety of Medicines (CSM). Cyprolerone acetate (Dianette): risk of venous thromboembolism (VTE). Current Problems in Pharmacovigilance 2002; 28: 9-10.
147. Piotrowski C, Sherry D, Keller JW. Psychodiagnostic test usage: a survey of the Society for Personal Assessment. J Pers Assess 1985; 49: 115.
148. Steer RA, Beck AT, Garrison B. Applications of the Beck Depression Inventory. In: Sartorius N, Ban TA (eds), Assessment of Depression. New York, NY: Springer-Verlag, 1985; 121.
149. Gupta N, O'Brien R, Jacobsen LJ, et al. Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study. J Pediatr Adolesc Gynecol 2001; 14: 71-76.
150. World Health Organization (WHO). Selected Practice Recommendations for Contraceptive Use. Geneva, Switzerland: WHO, 2002.
151. Faculty of Family Planning and Reproductive Health Care (FFPRHC). UK Selected Practice Recommendations for Contraceptive Use. London, UK: FFPRHC, 2002. http://www.ffprhc.org.uk.
152. Cromer BA, McCarthy M. Family planning services in adolescent pregnancy prevention: the views of key informants in four countries. Fam Plann Perspect 1999; 31: 287-293.
153. Teenage Pregnancy Unit, Department of Health. Best Practice Guidance on the Provision of Effective Contraception and Advice Services for Young People. London, UK: Teenage Pregnancy Unit, Department of Health, 2002; 1-5. http://www.info.doh.gov.uk/ tpu/tpu.nsf.
154. McLeod A. Changing patterns of teenage pregnancy: population based study of small areas. BMJ 2001; 323: 199-203.
155. Rowlands S. Raising standards in family planning services. Br J Gen Pract 1991; 41: 138-139.
156. Hughes D, McGuire A. The cost effectiveness of family planning service provision. J Public Health Med 1996; 18: 189-196.
157. Social Exclusion Unit. Teenage Pregnancy. London, UK: The Stationery Office, 1999.
158. Glasier A. Sexual Health Services for Young People. Young People and Sexual Health. Edinburgh, UK: Health Education Board for Scotland, 2002.
159. Scottish Executive. Enhancing Sexual Wellbeing in Scotland: A Sexual Health and Relationships Strategy Supporting Paper 5B: Supporting Access to Clinical Services and Reaching Those in Need. 2003. http://www.scotland.gov.uk/ library5/health/esws-00.asp.
160. Clements S, Slone N, Diamond I, et al. Modelling the spatial distribution of teenage conception rates within Wessex. J Fam Plann Reprod Health Care 1998; 24: 61-71.
161. Baraitser P, Fettiplace R, Massil H,et al. Quality, mainstream services with proactive and targeted outreach: a model of contraceptive service provision for young people. J Fam Plann Reprod Health Care 2002; 28: 90-94.
162. Garside R, Ayres R, Owen M, et al. Anonymity and confidentiality: rural teenagers' concerns when accessing sexual health services. J Fam Plann Reprod Health Care 2002; 28: 23-26.
163. McAllister KF, Elliot L, Thomson DAM, et al. Evaluation of a young person's sexual health service in a commercial setting. J Fam Plann Reprod Health Care 2002; 28: 203-205.
164. Teenage Pregnancy Unit. Developing Checklists: Guidance for Local Teenage Pregnancy Co-ordinators. London, UK: Teenage Pregnancy Unit, Department of Health, 2001; 1-11. http://www.info.doh.gov.uk/ tpu/tpu.nsf.
165. Paul C, Fitzjohn J, Herbison P, et al. The determinants of sexual intercourse before age 16. J Adolesc Health 2000; 27: 136-147.
166. Teenage Pregnancy Unit. Guidance for Developing Contraception and Sexual Health Advice to Reach Black and Minority Ethnic (BME) Young People. London, UK: Teenage Pregnancy Unit, Department of Health, 2001; 1-48. http://www.info.doh. gov.uk/tpu/tpu.nsf.
167. Teenage Pregnancy Unit. Guidance for Developing Contraception and Sexual Health Advice Services to Reach Boys and Young Men. London, UK: Teenage Pregnancy Unit, Department of Health, 2000; 1-52. http://www.info.doh.gov.uk/ tpu/tpu.nsf.
168. Royal College of Obstetricians and Gynaecologists (RCOG). The Care of Women Requesting Induced Abortion. London, UK; RCOG Press, 2004 (in press).
169. McFadyen J. Teaching sex education: are Scottish school nurses prepared for the challenge? Nurse Educ Today 2004; 24: 113-120.
170. Butler R, Solomon S. Review of Sexual Health Services for Young People in Scotland. Edinburgh, UK: Health Education Board for Scotland, 2002. http://www.hebs.scot.nhs.uk/research/pdf/ RE02820002001Final.pdf.
171. Hosie A. Sexual Health Policy Analysis in Selected European Countries. Edinburgh, UK: Health Education Board for Scotland, 2002.
172. Brook. Someone With a Smile Would be Your Best Bet. London, UK: Brook Publications, 2004. http://www.brook.org.uk.
173. Hippisley-Cox J, Allen J, Pringle M, et al. Association between teenage pregnancy rates and the age and sex of general practitioners: cross sectional survey in Trent 1994-7. BMJ 2000; 320: 842-845.
174. Faculty of Family Planning and Reproductive Health Care (FFPRHC). Service Standards for Work in Contraception. London, UK: FFPRHC, 2004.
175. Sex Education Forum. Sex and Relationships Education Framework. Forum Factsheet 30. London, UK: National Children's Bureau for the Sex Education Forum, 2003, 1-4. http://www.ncb.org.uk/sef.
176. Department for Education and Environment (DfEE). Sex and Relationship Education Guidance. Nottingham, UK: DfEE Publications, 2000; 1-35. http://www.dfes.gov.uk/sreguidance/ sexeducation.pdf.
177. Scottish Executive. Sex Education in Scottish Schools: Summary of National Advice. Queen's Printers for Scotland, 2004.
178. Scottish Executive. National Health Demonstration Projects' Annual Report 2001 - Learning to Make a Difference. 2001. http://www. Scotland.gov.uk/ library5/health/ltmd-00.asp.
179. fpa. Sex and Relationships Education. Factsheet No. 10. London, UK: fpa, 2004.
180. Lindsay J, Smith AMA, Rosenthal DA. Conflicting advice? Australian adolescents' use of condoms or the pill. Fam Plann Perspect 1999; 31: 190-194.
181. Hacker KA, Amare Y, Strunk N, et al. Listening to youth: teen perspectives on pregnancy prevention. J Adolesc Health 2000; 26: 279-288.
182. Olsen CL, Santarsiero EC, Spatz D. Qualitative analysis of African-American adolescent females' beliefs about emergency contraceptive pills. J Pediatr Adolesc Gynecol 2002; 15: 285-292.
183. Hansen T, Skjeldestad FE. Communication about contraception and knowledge of oral contraceptives amongst Norwegian high school students. J Adolesc 2003; 26: 481-493.
184. Aneblom G, Larsson M, Odlind V, et al. Knowledge, use and attitudes towards emergency contraceptive pills among Swedish women presenting for induced abortion. Br J Obstet Gynaecol 2002; 109: 155-160.
185. Haggstrom-Nordin E, Tyden T. Swedish teenagers' attitudes toward the emergency contraceptive pill. J Adolesc Health 2001; 28: 313-318.
186. Graham A, Green L, Glasier AF. Teenagers' knowledge of emergency contraception: questionnaire survey in south east Scotland. BMJ 1996; 312: 1567-1569.
187. Goold PC, Ward M, Carlin EM. Can the Internet be used to improve sexual health awareness in web-wise young people? J Fam Plann Reprod Health Care 2003; 29(1): 28-30.
188. Kane R, Macdowall W, Wellings K. Providing information for young people in sexual health clinics: getting it right. J Fam Plann Reprod Health Care 2003; 29(3): 141-145.
189. Department for Education and Skills. Working Together: Giving Children and Young People a Say (Consultation). London, UK: Department for Education and Skills, http://www.dfes.gov.uk/ consultations2/18/docs/WORKING_TOGETHER.doc. 2003.